Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event
- 1 January 2014
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 47 (1) , 138-145
Abstract
We investigated the efficacy of cilostazol treatment for 2 years on the attenuation of carotid intima-media thickness (IMT) progression in type 2 diabetic patients without cardiovascular disease history, as compared with other antiplatelet agents. We recruited a total of 230 type 2 diabetic patients who had undergone IMT measurement twice within 1.5–2.5 years (mean 2.06 ± 0.32 years) interval. Among these participants, we classified them into three groups according to antiplatelet agent administration at baseline: Group I (n = 66), antiplatelet naïve; Group II (n = 75), other antiplatelet agent administration; and Group III (n = 50), cilostazol administration. We then analyzed the changes in clinical characteristics from baseline to 2 years. The changes in annual mean IMT at 2 years were 0.019 ± 0.045 mm/year, −0.001 ± 0.058 mm/year, and −0.019 ± 0.043 mm/year for Group I, II, and III, respectively (P < 0.001). Mean change in total cholesterol, low-density lipoprotein-cholesterol, and triglyceride compared with baseline decreased the most in Group III even after adjustment for statin use. We also observed that the odds ratio of carotid IMT progression at 2 years was the lowest in patients who were treated with cilostazol even after adjustment for change of metabolic parameters. When we categorized patients according to baseline carotid IMT tertile, the efficacy of cilostazol against carotid IMT progression was significant only when baseline IMT was over 0.662 mm (mean 0.801). Two-year treatment with cilostazol strongly inhibited carotid IMT progression compared to other antiplatelet agents in type 2 diabetic patients. This beneficial effect of cilostazol was significant when baseline IMT was thicker than 0.662 mm (mean 0.801 mm).Keywords
This publication has 30 references indexed in Scilit:
- Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Expert Opinion on Pharmacotherapy, 2011
- Cilostazol Inhibits Oxidative Stress–Induced Premature Senescence Via Upregulation of Sirt1 in Human Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patientsPharmacological Research, 2007
- Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes MellitusCirculation, 2005
- Cilostazol as a Unique Antithrombotic AgentCurrent Pharmaceutical Design, 2003
- Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategiesNature Medicine, 2002
- Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media ThicknessCirculation, 2001
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Prevalence of Carotid Atherosclerosis in Diabetic Patients Ultrasound high-resolution B-mode imaging on carotid arteriesDiabetes Care, 1992
- Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart StudyDiabetes Care, 1992